NERV | Minerva Neurosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.1208 - 2.3900
52 Week Range	2.0600 - 13.49
Beta	-0.62
Implied Volatility	410.71%
IV Rank	83.29%
Day's Volume	41,182
Average Volume	24,672
Shares Outstanding	6,993,410
Market Cap	16,294,645
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-07-01

Valuation
Profitability
Growth
Health
P/E Ratio	-5.18
Forward P/E Ratio	N/A
EPS	-0.45
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	9
Country	USA
Website	NERV

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

NERV's peers: RVPHW, EYEN, CGTX, RNAZ, KOD, ZURA, ANNX, ICVX, INAB, WVE, DAWN, ABOS, XFOR, INZY, VECT, ALXO, CABA, VIRX, EYPT, BMEA, MREO, TERN, LPTX

*Chart delayed

Analyzing fundamentals for NERV we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see NERV Fundamentals page.

Watching at NERV technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NERV Technicals page.